As cannabidiol (CBD) use rises, high quality randomized clinical trials are needed to determine if anti-inflammatory benefits of CBD for heart disease seen in preclinical data will work in a real-world setting, according to research presented at ACC Latin America 2022 Together with CardioAcademic. A review of existing studies found no clinical recommendations can be made given current evidence. ACC Latin America 2022 Together with CardioAcademic will be held in Mexico City on September 9–10, 2022.
You may also be interested in:
Researchers are joining forces with the food and health industries to tighten controls and improve nutrition for infants and children.This article was originally published on [...]
Toddlers whose moms were exposed to higher levels of air pollution during mid- to late-pregnancy tend to score lower on measures of cognition, motor coordination [...]
When visiting friends or family who have both houseplants and young children, I’ve been compared to “Aunt Bonnie” from the Geico commercial “Aunt Infestation.”This article [...]